SerpinB3 administration protects liver against ischemia-reperfusion injury

Eur J Histochem. 2022 Oct 28;66(4):3561. doi: 10.4081/ejh.2022.3561.

Abstract

We have investigated the change in SerpinB3 during hepatic ischemia and the potential role of its antiprotease activity in cell protection by the administration of wild-type SerpinB3 (SerpinB3-WT) or active loop-deleted recombinant SerpinB3 protein (SerpinB3-D) in a rat model of ischemia (60 min)/reperfusion (60 min) (I/R). A time-dependent increase of SerpinB3, both at transcription and protein level, was found in ischemic livers after 60, 120 and 180 min. SerpinB3-WT decreased polymorphonuclear cell infiltration and serum enzymes and increased ATP when compared with I/R group. These events were not obtained using SerpinB3-D. No significant changes in both liver SerpinB3 mRNA and protein were found in all I/R groups considered. The present data show that the administration of SerpinB3-WT reduced the I/R injury and this effect appears to be dependent on its anti-protease activity.

MeSH terms

  • Animals
  • Ischemia / metabolism
  • Liver*
  • Rats
  • Reperfusion Injury* / metabolism
  • Reperfusion Injury* / prevention & control

Grants and funding

Funding: This work was supported in part by LifeLab Program of the ‘Consorzio per la Ricerca Sanitaria (CORIS) of the Veneto Region, Italy (DGR1017, 17 July 2018).